Premium
Non‐steroidal anti‐inflammatory drugs and Helicobacter pylori
Author(s) -
Barr M.,
Buckley M.,
O'morain C.
Publication year - 2000
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.2000.00399.x
Subject(s) - medicine , helicobacter pylori , asymptomatic , gastroenterology , spirillaceae , clinical trial , secretion , gastritis
Summary Non‐steroidal anti‐inflammatory drugs (NSAIDs) and Helicobacter pylori are well‐recognized causes of gastroduodenal mucosal damage. This damage is mediated through the effects of both agents on acid secretion, neutrophil activity and function, and prosta‐ glandin metabolism. Clinical trials on the interrelation‐ ship between H. pylori , NSAIDs and gastroduodenal mucosal injury have yielded conflicting results. No consensus has been reached on what recommenda‐ tions should be implemented with regard to H. pylori eradication in patients on long‐term NSAID therapy. At present, the presence of H. pylori is identified at endoscopy and eradication is carried out in symptomatic patients. Asymptomatic patients remain a dilemma that requires further investigation. Clinical practice will continue to be tailored to a patient's individual requirements. Therefore, in patients at risk of gastrointestinal haemorrhage, and on NSAID therapy, acid suppression therapy should be prescribed.